Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
NCT00880308
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
103
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor Cancers
Medulloblastoma
Basal Cell Carcinoma
Interventions
DRUG:
LDE225
Sponsor
Novartis Pharmaceuticals